The Massachusetts Life Sciences Center (MLSC) announced today the awarding of $1.5 million in Accelerator loan financing to two promising early-stage companies, Lexington-based MX Orthopedics Corp, and Bedford-based First Light Biosciences Inc.
MX Orthopedics Corp., Lexington – $750,000
First Light Biosciences Inc., Bedford – $750,000
The Massachusetts Life Sciences Center (MLSC) announced today that the agency will launch an open solicitation for life-sciences-related capital projects on May 27th, and an open solicitation for high school and middle school equipment & supply grants on May 31st. Funding for both programs was included in the Baker/Polito Administration’s capital plan that was released yesterday. The Administration’s Fiscal Year 2017 capital plan provides $63.6 million for the Massachusetts Life Sciences Center, a 15% increase over the Center’s projected spending of $55 million in FY16.
The Massachusetts Life Sciences Center and the BioBuilder Educational Foundation held their first-ever graduation ceremony for Life Sciences High School Apprentices at LabCentral in Cambridge. Twenty-seven students from Boston and Cambridge have successfully completed an eight-week lab-readiness training program as part of the newly established Life Sciences High School Apprenticeship Challenge training program, the pilot year of which was funded by a $50,000 grant from the Massachusetts Life Sciences Center (MLSC).
Web Industries, Inc., innovative provider of precision contract manufacturing and converting services, is proud to announce the opening of the company’s first lateral flow immunoassay (LFI) production facility. Co-located within the company’s existing Web Boston location, the Lateral Flow Diagnostics Center of Excellence will provide companies marketing LFI tests with a one-stop outsource manufacturing solution that offers a reliable path from small-scale test development to high-volume commercialization of new LFI devices. The 6,500 square foot environmentally-controlled facility was purpose-built for automated reel-to-reel medical device production and features an in-house biochemistry lab, reagent deposition, LFI strip manufacturing, device assembly, and packaging stations.
The Baker-Polito Administration announced $20 million in tax incentive awards, to 28 life sciences companies. The awards, which will create 1,325 new jobs in the Commonwealth in 2016, were approved today by the Board of Directors of the Massachusetts Life Sciences Center (MLSC). The tax incentive awards will support life sciences job growth in fourteen Massachusetts cities and towns; half of the awardees are located or are expanding outside of Greater Boston.
|908 Devices Inc.||Boston||$165,000||11|
|Alnylam Pharmaceuticals, Inc.||Cambridge||$2,250,000||150|
|Baxalta US, Inc.||Cambridge||$1,320,000||66|
|Charles River Laboratories, Inc.||Wilmington||$1,200,000||80|
|Enanta Pharmaceuticals, Inc.||Watertown||$360,000||24|
|Ginkgo Bioworks, Inc.||Boston||$483,377||50|
|Juno Therapeutics, Inc.||Waltham||$165,000||11|
|LFB USA, Inc.||Framingham||$720,000||48|
|Masy Systems, Inc.||Pepperell||$150,000||10|
|Merrimack Pharmaceuticals, Inc.||Cambridge||$225,000||15|
|Moderna Therapeutics, Inc.||Cambridge||$1,875,000||125|
|Nitto Denko Avecia Inc.||Milford||$450,000||30|
|Nova Biomedical Corporation||Waltham||$750,000||50|
|Radius Health, Inc.||Waltham||$525,000||35|
|Sarepta Therapeutics, Inc.||Cambridge||$750,000||50|
|Seres Therapeutics, Inc.||Cambridge||$945,000||63|
|Shire Human Genetic Therapies, Inc.||Lexington||$2,250,000||150|
|Siemens Healthcare Diagnostics, Inc.||Walpole||$735,000||30|
|SQZ Biotechnologies Company||Boston||$129,784||20|
|STC Biologics, Inc.||Cambridge||$150,000||10|
|Takeda Pharmaceuticals America, Inc.||Cambridge||$1,125,000||75|
|Web Industries Boston, Inc.||Holliston||$150,000||10|
Regis College announced the opening of their newly renovated life science training facility. This more than 800 square-foot science laboratory, enhanced with new state-of-the-art scientific equipment, was enabled by a $355,000 capital grant from the MLSC. This facility will position Regis College to better prepare students for careers in the life sciences.
Anagenesis Biotechnologies, a company developing stem cell-derived treatments for muscle diseases, announced the creation of its US subsidiary, Anagenesis Biotherapies Inc. with offices at the Cambridge Innovation Center’s 50 Milk Street facility in Boston, Massachusetts. The US subsidiary will carry out the company’s cell therapy programs with an initial focus on Duchenne Muscular Dystrophy (DMD), paving the way for future partnerships.
CeQur® announced that the company is doubling the size of its Marlborough facilities in preparation for the launch of PAQ®, the company’s simple, three-day insulin infusion device. When completed later this year, the Marlborough facility will total 25,000 square feet, including a new clean room, labs and a manufacturing line. CeQur anticipates the expanded space will house 150 employees – the company’s 50 current employees, in addition to more than 100 employees CeQur plans to hire over the next 24 months.
Affera has announced its move to a larger facility on 44 Pleasant Street, along the Charles River in Watertown. Affera is a venture-backed medical device company founded by a seasoned team of industry leaders. The company is developing an innovative system for the treatment of heart rhythm disorders, one of the fastest growing fields in medical devices.
The Massachusetts Life Sciences Center (MLSC) announced the launch of the 2016-17 Internship Challenge program. This year’s program will feature a $700,000 increase in funding, an increase in the maximum reimbursable pay rate for interns from $15/hour to $17/hour, and a new incentive for long-term hiring by participating companies. Under the new hiring incentive companies that offer a long-term position to a participating intern will be able to receive funding for a replacement intern.
Biognosys, a Swiss next-gen proteomics company announced that it will open its new North American office in Greater Boston, Massachusetts in Q2 this year. The office will be the firm’s first North American location. The Massachusetts Life Sciences Center has worked closely with Biognosys on their location selection decision.
Emulate, Inc., announced the official opening of its new headquarters and laboratories in Boston’s Seaport District, at 27 Drydock Avenue within The Innovation and Design Building. The new facility will be a workplace for the company’s 40 employees, with plans for expansion to 85 employees within the coming year.
Emulate located its new headquarters to facilitate collaborations within Boston’s biotechnology hub of pharmaceutical and biotech companies who are using the Organs-on-Chips technology to better predict the potential efficacy and safety of drug candidates, and to improve the drug development process.
The new expansion enables Simcere to provide additional functions to all our clients, and to be a part of one of the world’s leading ecocystems for life sciences innovation in the Greater Boston region. The company also announced that it is a sponsor for an international startup contest in life science, especially in precision medicine and e-health. The co-sponsors include influential Chinese industrial investors, pharmaceutical companies and Chinese media with the support of a powerful alliance of strategic investors. The event runs from January to May 2016. It will take place in 8 cities in both China and the US, with the US preliminaries held in San Francisco and Boston.
The Massachusetts Life Sciences Center (MLSC) announced that applications are now being accepted for a new round of the Job Creation Tax Incentive Program. The Program offers tax incentives to encourage the growth of companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Through this year’s program, the MLSC will seek to leverage the life sciences assets that are now in place around the state, and promote growth throughout Massachusetts. Toward that end, the agency is actively encouraging applications from companies located outside of Greater Boston.
The Massachusetts Life Sciences Center (MLSC), announced the launch of the twelfth round of its Accelerator Loan Program, the MLSC’s flagship investment program that provides working capital to early-stage life sciences companies.
In the new round, the Accelerator program will offer loans of up to $750,000 per company. The program seeks to provide support to companies at a critical stage of their development cycle, enabling them to conduct vital research and proof of concept studies, and attract subsequent investment while improving the odds of bringing cutting-edge innovation to the marketplace.